TB-4 usually means beta-4 thymosin, a naturally occurring peptide studied for its role in actin regulation and various processes related to tissue repair. Its biological identity is well known, however evidence regarding externally administered preparations depends on the specific disease, route of administration, and study design. Human studies do not justify treating all online claims about „TB-4 benefits” as established clinical uses.[1]
It is fundamental to distinguish the full beta-4 thymidine molecule and its shorter fragments. In particular, FDA materials describe TB-500 as an N-acetylated fragment composed of seven amino acid residues. It should not be automatically attributed clinical evidence regarding the full molecule used in an ophthalmic preparation or recombinant only because both names are often used together online.[2]
What is TB-4? Names, synonyms and identity
Thymosin beta-4 is listed in publications under the names Tβ4, Tbeta4, TB4, and thymosin β4. In molecular databases, the human peptide is associated with the TMSB4X gene and the historical name Fx. Studies have shown that Fx, the monomeric binding factor of actin, and thymosin beta-4 are the same molecule.[1][3]
When searching for literature, it is worth separating the nomenclature of genes and proteins from the development codes of the preparations. TMSB4X is the designation of a gene, whereas thymozine beta-4 is the corresponding biological product. These identifiers are related, but the study of the RNA information expression of the TMSB4X gene does not necessarily mean measuring the concentration of mature peptide directly. Antibody-based tests, mass spectrometry methods, and gene expression measurements can describe different biological quantities.
The labeling of a clinical preparation is also not interchangeable with the name of its active substance. The preparation has its own auxiliary substances, concentration, packaging, batch release specifications, and stability data. Even if the sequence of active substances is correct, additional properties can affect experimental exposure and the interpretation of adverse events. This is particularly important when comparing an ophthalmic solution with a topical preparation or a material administered by another route of administration.
The scientific name provides more information than the trade abbreviation. The publication may concern the endogenous expression, the synthetic copy of a peptide, a recombinant preparation, a fragment, or a specific clinical formulation. These are related issues, but they answer different questions. Measuring one's own body peptide does not confirm the action of the product delivered from the outside.
RGN-259 is an ocular preparation under investigation that contains betamethasone beta-4. The results of its studies refer to a specific product in the form of eye drops, not to any vial labeled with a similar name. The same caution applies to experimental topical formulations used in wound studies and recombinant products used in systemic studies. The product identity includes information regarding the manufacturing and formulation, not solely the sequence nomenclature.
How is TB-4 classified? Peptide, protein, mixture, or other substance?
Mature thymosin beta-4 is usually described as a peptide composed of 43 amino acids with a mass of about 5 kDa. Protein databases can also classify it as a small protein. This is an overlap of terminology rather than evidence of the existence of two unrelated substances. Its mature chain is short enough to correspond to the conventional definition of a peptide, while at the same time it is a biological product encoded by a gene.[4][3]
The terminology regarding peptides and proteins does not have a universally accepted length limit for the chain. The practical distinction lies in the fact that mature TB-4 is a specific, genetically encoded 43-residue chain, whereas TB-500, according to the definition adopted in the regulatory analysis cited, is a seven-residue derivative. The structural description should take into account the number of residues and terminal modifications, rather than relying solely on the category name.
The second distinction concerns naturally present TB-4 and synthetic or recombinant material. The localization, concentration, and processing of endogenous peptide are regulated by biological systems. The produced peptide may be chemically comparable to the natural sequence, but differ in delivery mode, exposure, impurities, and formulation form. The mere chemical similarity does not confirm pharmacological or clinical equivalence.
The molecule itself is not a plant compound, a steroid, or a growth hormone releasing peptide. However, the finished preparation also contains other ingredients and must be evaluated as a whole. The natural presence of the peptide does not confirm the safety of a specific externally administered preparation or the given exposure.
Distinguishing fragments is particularly important. The 2026 FDA advisory materials on the preparation of prescription drugs identify TB-500 as N-acetyl-LKKTETQ. The short motif derived from the larger peptide has a different molecular identity and may exhibit different stability, distribution, and biological activity. The common amino acid residues do not confirm therapeutic equivalence.[2]
The structure and composition of TB-4 – what has been established?
The mature human molecule has an acetylated amino terminus. The sequence in the database may contain 44 residues, because it includes the initiating methionine, which is removed during processing. The commonly used description of a mature peptide includes 43 residues. The length of the sequence should therefore be interpreted together with the processing annotations, rather than treating the difference as an unexplained contradiction. [3]
N-terminal acetylation of a mature peptide is a covalent modification and forms part of its molecular identity. It should not be confused with acetate anions in the delivered salt or with the acetylated short fragment. These are different chemical properties: the attached terminal group, the ionic component of the preparation, and the separate peptide chain. Identifying them can lead to errors in analytical interpretation.
The binding motif of an actin is often discussed because it helps explain biochemical activity. However, the identification of the motif itself does not determine the affinity of each fragment under physiological conditions. Binding may depend on neighboring residues, conformational preferences, competing proteins, ionic conditions, and the measurement method used. The fragment should be studied as a separate molecule with its own concentration and appropriate controls.
Quality assessment may require complementary analytical methods. Chromatography can describe the distribution of detected components, while mass spectrometry can confirm molecular identity. Neither the dominant chromatographic peak nor the consistent molecular mass alone confirm all stereochemical properties, biological activity, or microbiological properties. Claims regarding the quality of batches should remain within the limits of the studies actually conducted.
The binding region of an actin molecule is part of a complete chain, but knowledge of the binding motif does not mean that the remaining part of the molecule is unimportant. The molecular context can influence affinity, conformation, susceptibility to degradation, and interactions with other biological partners. The fragment also does not necessarily replicate all the activities attributed to the intact peptide.
The description of the research material should include the full sequence or specification of the identity, the chemistry of the end groups, purity, peptide content, formulation, and route of administration. The percentage of chromatographic purity alone does not confirm identity, neutrality, endotoxin control, or equivalence to the product used in the clinical study. These are separate analytical and production issues.
The endogenous peptide and the externally administered preparation also reach different environments. It should not be assumed that intracellular quantity, extracellular exposure, and delivery to a specific tissue are interchangeable. A convincing translational argument must link the produced material to the exposure and the biological response relevant to the proposed application.
Studies on TB-4 – evidence in humans, animals and in the laboratory
Basics of laboratory research
One of the basic biochemical studies showed that thymozine beta-4 binds actin monomers in a 1:1 ratio complex and inhibits their polymerization under experimental conditions. In this way, an important cellular function was established; however, this was not a wound treatment study. The biological mechanism can be well confirmed, while the therapeutic application remains uncertain.[1]
Actin exists in monomeric and filamentous forms, and the transitions between these forms support the architecture and movement of cells. The binding of monomeric actin is a measurable biochemical interaction. However, it does not represent the same endpoint as increased tissue strength or accelerated healing. The biological effects of changes in actin dynamics depend on the type of cell, its initial state, and the presence of other regulators.
The original biochemical observation is valuable precisely because it concerns a specific molecular event. Later hypotheses regarding cell migration, wound closure, or tissue remodeling require additional experiments that combine molecular activity with cell behavior, and then with the results in a complex tissue. This chain of evidence should not be reduced to a single statement.
Ophthalmological studies involving humans
Nine patients participated in a small randomized study regarding severe dry eye syndrome. Improvement in selected symptoms and clinical parameters was reported. The small number limits the precision and the possibility of generalizing the results. The numbers of eyes evaluated should not be confused with the number of independent participants. [5]
Dry eye studies often include both objective measurements of eye surface and scales of symptoms. These results do not have to be correlated because different factors influence the symptoms and signs on the surface. When the study identifies two equivalent primary endpoints, the success criteria are important. A positive signal at the secondary endpoint cannot automatically replace the unmet primary endpoint. The report should indicate the date of assessment, the definition of the endpoint, the difference between the groups, and the statistical uncertainty.
In the published ARISE-3 study, the mean group results provide useful descriptive context, but the lack of a clear separation of groups in the presented summaries does not in itself constitute a complete reanalysis of the study. Interpretation should be based on the full protocol, statistical analysis plan, and the results presented appropriately if available. Equally misleading would be announcing efficacy based on the study phase alone or claiming that any possible outcome in subgroups has been definitively excluded.
The results of the neurotrophic corneal inflammation study show a difference between the numerical contrast and the conventionally statistically significant primary comparison. The observed recovery rates may justify further studies, but the small sample size and the p-value reported after four weeks limit the certainty of the conclusion. A subsequent favorable observation should be interpreted in light of the measurement time, the analysis plan, and the possibility of multiple comparisons occurring.
In a separate Phase II study involving 72 participants, no significant treatment advantage was demonstrated in any of the two primary endpoints at the designated time point of evaluation. Some secondary results favored RGN-259. This distinction is more important than the article’s optimistic title or its final conclusion. Secondary results can guide further research, but they do not make the primary primary analysis positive. [6]
The larger ARISE-3 study registry includes results for 700 enrolled participants. In the published summaries of primary endpoints, the mean change in ocular discomfort was −0.4 in both groups, while the mean changes in colorimetric parameters were −0.41 and −0.46. Descriptive results do not show a clear separation of groups. In this review, they are not assigned a significance test, which is not presented in the available tables of primary results. [7]
18 people participated in the neurotrophic corneal inflammation study. Complete healing occurred after four weeks in 6 out of 10 participants treated and in 1 out of 8 people in the control group, with p = 0.0656. Subsequent evaluation indicated the benefit of the treatment. The result after four weeks should be described as uncertain rather than being transformed into a statement of statistically confirmed efficacy. [8]
Studies on rats in humans
73 patients participated in a randomized phase II study regarding venous ulcers. Acceptable tolerability and possible signs of improved healing were reported at one of the tested concentrations. The results justified further research rather than the universal claim that TB-4 treats all wounds. Venous ulcers constitute a specific disease entity that is also associated with standard therapeutic treatment procedures.[4]
Lower limb venous ulcers are influenced by venous circulation, local inflammation, wound care, and patient characteristics. Therefore, study results cannot be separated from primary treatment and applied to unrelated injuries. Healing endpoints may include wound area reduction, complete closure, and time to closure. These should be reported separately.
The signal obtained in phase II is intended to serve as a basis for planning further studies, including the selection of endpoints and the estimation of variability. It does not necessarily constitute definitive confirmation of a lasting therapeutic effect. Long-term recurrences and functional outcomes may require observation beyond the initial wound assessment.
Translational studies regarding the heart
The 2025 report combined experiments on mice and cells with a randomized study involving 96 patients after myocardial infarction and coronary intervention. The clinical analysis showed no significant overall difference in the areas affected by the infarction. However, a favorable result was obtained in the subgroup defined based on the earlier initiation of treatment. Laboratory studies analyzed ErbB2-related signaling. This is a signaling signal requiring confirmation rather than established evidence of overall effectiveness of myocardial repair. [9]
The cardiology study combined various levels of evidence: signaling experiments, animal models, and randomized comparisons in humans. Laboratory results may support the proposed biological pathway without determining the magnitude of clinical benefit. Therefore, the results of the randomized comparison are essential when assessing the claim that the intervention reduces myocardial damage in the studied population.
The results of subgroups identified based on the time of initiation of treatment require particularly cautious interpretation. The subgroup may differ in initial disease severity, course of care and number, and a favorable comparison may be unstable without prospective confirmation. A reliable follow-up study should previously determine the criteria for initiating treatment, utilize a clinically relevant primary endpoint, and report both the entire population and the subgroup without treating them as interchangeable.
These studies also show why the statement „there is evidence in humans” is not a complete conclusion. Important questions concern which patients were studied, what preparation was used, what comparator was used, what was the primary endpoint and how much uncertainty remained. The ophthalmological results regarding ulcers and cardiac events cannot be informally combined into a general claim of regeneration.
Mechanism of action studied for TB-4
Actin regulation constitutes a well-documented molecular starting point. Cell movement and tissue organization involve coordinated changes in actin dynamics, making the related hypotheses regarding tissue repair biologically plausible. However, the mechanism demonstrated in the purified system does not specify effective exposure or a balance of benefits and risks in the patient.[1]
Discussions regarding thymoquinone beta-4 often involve several mechanistic levels. The binding of actin monomers is a direct molecular interaction. Cell migration constitutes a functional response of the cellular population. Cell membrane closure is the endpoint at the tissue level, while restoring strength or function constitutes an even broader result. Evidence at one level may justify a hypothesis regarding the next, but each transition requires appropriate measurements.
Biological activity can also vary depending on local concentration, peptide degradation, and the extracellular environment. The presence of endogenous TB-4 at the injury site does not mean that increasing external exposure will improve the repair process. Expression can increase in response to injury, not as a factor limiting the rate of regeneration. Local observations and intervention experiments address different questions.
When discussing signaling related to ErbB2, conclusions should be limited to a specific model. Inhibiting the proposed pathway and observing a modified response can strengthen the mechanistic interpretation in this system. However, they do not clinically confirm a validated mechanism in all tissues or the functional benefit in healthy individuals.
Clinical and translational publications analyzed cell migration, epithelial repair, inflammatory responses, and cardiomyocyte survival signaling. These mechanisms operate at different levels and in different models. In a cardiology study, ErbB2 inhibition had an experimental benefit in mice, reinforcing the proposed mechanism in this model. However, it did not confirm that the same pathway is responsible for clinical benefit in every patient [9].
The description of the mechanisms should remain precise. The term „supports recovery” can refer to a molecular marker, a migration test, a wound surface change, or the restoration of function. Each of these results has a different weight of evidence. A decrease in the laboratory marker value does not confirm a faster return to sport, sustained tendon strength, or an improvement in daily functioning.
The relationship between the full-length peptide and its fragment also requires direct experiments. The FDA analysis regarding TB-500 highlights the limited number of evidence specific to this fragment. It is not scientifically justified to use literature regarding intact peptide as if it were clinical documentation of a shorter molecule. [2]
Limitations of the scientific evidence regarding TB-4
Several limitations repeat in the studies: small early clinical trials, selectively emphasized positive secondary results, formulations specific to specific diseases, and the uncertainty of transferring results from experimental models to humans. The presence of a Phase III study does not guarantee a positive outcome, and a favorable result in a subgroup does not replace analysis of the entire population. These distinctions should be visible in any summary of the evidence.
The quality of the evidence cannot be reduced to the number of publications listing the peptide. A mechanistic article, a small feasibility study, a randomized Phase II study, and a clinical trial registry provide different information. They should not be treated as equivalent confirmations of clinical efficacy. The most relevant evidence involving human participants depends on the consistency of the declared disease, formulation, comparison, and endpoint.
Another limitation is the selective emphasis on results. Reporting beneficial secondary measurements while ignoring previously defined primary results can distort the evidence picture. There is also the possibility of a counter-effect: a negative primary result does not mean that all mechanistic observations are false. A proper description retains both the experimental result and the limitations of its clinical significance.
Safety issues include immunological reactions, formulation-related events, local tolerance, and risk related to route of administration or repeated exposure. Limited early studies may detect common short-term reactions, but do not allow for reliable assessment of rare or delayed damage. Evidence regarding topical or ocular product cannot automatically determine the safety profile of the non-systemic formulation.
The reviewed studies do not establish a general protocol for bodybuilding, tendon repair, or improved well-being. Such claims would require appropriate human studies with objective functional outcomes and sufficient long-term safety observations. An ophthalmological study does not answer questions regarding systemic use, similarly to a post-myocardial infarction study that does not confirm improved performance in healthy individuals.
Short-term tolerance should also be distinguished from a complete safety profile. Rare adverse events, repeated exposure, interactions, and effects in underrepresented populations require larger or longer studies. Naturally occurring molecules in the body can also exhibit exposure-dependent effects when delivered externally.
The regulatory interpretation should refer to the exact product and jurisdiction. The FDA committee’s cited document is a review of a peptide fragment, not an approval to market that fragment or the full molecule TB-4. Similarly, the clinical trial registry confirms the existence of a study, not the approval of a drug or its clinical efficacy.
Frequently asked questions about TB-4
1. Does TB-4 mean one defined substance?
In a well-defined scientific context, TB-4 usually means beta-4 thymozine. Trade abbreviations are less reliable, and fragments or otherwise formulated materials may appear under related names. Therefore, to match a claim to evidence, one must identify the exact molecule and product, not merely the abbreviation. A database record can confirm the canonical biological identity, but not the commercial vial. Research comparisons should determine whether natural material, chemically synthesized chain, or a ready-made preparation was used. If the source omits this information, uncertainty should be clearly stated.
2. What do the available studies on TB-4 confirm?
They confirm an important biological function associated with actin and document human studies in selected diseases. Clinical results are mixed and depend on the context, including studies that did not achieve primary endpoints. The evidence supports further research focused on specific indications rather than a universal claim of tissue repair. [1] [6] The strongest evidence relates to a specific interaction with actin, while clinical conclusions depend on each study. For example, ophthalmological studies differ in number of participants and primary endpoints, and the cardiology report does not show a significant overall advantage in the stroke area. Combining these results into a generalized claim of efficacy would distort the picture of the studies.
3. Is TB-4 the same as TB-500?
Their equivalence should not be assumed. The FDA describes TB-500 as an acetylated heptapeptide fragment, whereas mature beta-4 thymozine contains 43 residues. Therefore, evidence regarding the full molecule cannot automatically confirm the activity of a product identified by the fragment name.[2] The cited FDA document identifies TB-500 as N-acetyl-LKKTETQ. This structural definition is more useful than the online nomenclature conventions that may vary. Any claim that another material exhibits identical activity would require direct chemical and biological comparison, rather than relying on common thymozine terminology.
4. Why do some sources list 43 amino acids, and others list 44?
They can describe different stages of processing. The encoded sequence contains the initiating methionine, whereas the mature form is usually counted after its removal. The comparison of sequences should include processing and annotations regarding the chain ends before accepting that the sources describe different peptides. [3] Gene translation and posttranslational processing constitute separate stages. The initiating portion may occur in the precursor sequence, but not in the final mature product. Technically, a complete comparison should also include terminal acetylation, which may be part of the identity of the mature peptide.
5. Is naturally occurring TB-4 automatically safe to administer?
No. Natural occurrence does not confirm the safety of the produced product, the level of exposure, the route of administration, or the duration of use. Clinical safety must be evaluated for the administered product and the target population. The mere presence of the endogenous peptide does not provide such an assessment. The body regulates its own peptide in a cellular context different from that supplied from the outside. Appropriate safety evidence should characterize the actual product and exposure. Natural occurrence should not be used as either a guarantee of safety or as a reason to disregard justified biochemical studies.
6. Does actin binding prove that TB-4 builds muscle?
No. Binding of actin describes molecular interaction, not an increase in muscle mass, strength, or athletic performance. The claim regarding bodybuilding would require appropriate results in humans and control groups. It cannot be derived solely from the peptide’s involvement in cytoskeletal structure.[1] Muscle growth requires evaluation of parameters such as measured muscle mass, strength, and function in the appropriate population. The actin binding experiment in the purified system does not measure these results. Furthermore, cytoskeletal regulation occurs in many cell types and cannot be equated with anabolic action.
7. Do eye drops studies confirm the effectiveness of injections?
No. The local ocular exposure and the systemic exposure differ significantly in terms of the research questions and the appropriate safety assessments. The results refer to the studied product and indication, therefore the result regarding the eye drops does not replace the product administered by injection. The eye is a characteristic local environment, and ocular products are designed for a specific surface area. Different routes of administration alter the distribution, formulation requirements, and issues regarding adverse events. Therefore, the results of the local ocular study cannot be used to infer the overall systemic effect.
8. Does „Phase III” mean that the effectiveness of the treatment has been proven?
No. The study phase describes the stage of development, not its outcome. The study of neurotrophic corneal inflammation shows why actual endpoints and uncertainty are important. The favorable numerical difference after four weeks did not exceed the conventional statistical significance threshold of 0.05. [8] The study phase determines the intended development framework, not whether the hypothesis was confirmed. The study may reach a late phase and still show an uncertain or negative primary outcome. The basis for interpretation remain the population of participants, previously defined endpoints, and complete statistical results.
9. Can secondary positive results outweigh the unmet primary endpoint?
They may justify further studies, but they do not invalidate the primary result. Numerous measurements increase the possibility of accidental observations, therefore confirmatory studies should prospectively verify promising secondary signals, rather than presenting the primary study as unequivocally successful. [6] Secondary results are valuable if they are presented clearly and analyzed with consideration of multiple comparisons. They can help in designing the next confirmatory study. However, they should not be presented as if they meet the primary success criterion when that criterion has not been achieved.
10. Does the study of ulcers prove that TB-4 repairs damaged tendons?
No. Ulcers and tendon injuries differ in tissue type, disease mechanism, loading, and clinically relevant outcomes. The study of venous ulcers provides evidence for a specific research setting. Claims regarding tendon strength or return to activity require studies designed to assess these parameters.[4] Venous ulcers involve tissue structures and clinical factors other than tendons. Tendon regeneration would require appropriate assessment of load tolerance, structural integrity, pain, and functional fitness. The study of ulcers did not provide such measurements, therefore the proposed extrapolation has no support.
11. Does a cardiology examination confirm the benefit after every heart attack?
No. The report did not show a significant overall difference in the area of stroke, although the outcome in the previously treated subgroup was favorable. The subgroup results require careful confirmation, especially when they are used to support a claim broader than that of the overall study result. [9] A general randomized comparison provides a starting point for interpreting clinical efficacy. A subgroup defined by the time of initiation of treatment may suggest a hypothesis, but its result may be limited in precision and susceptible to selection. Confirmation would require a prospectively designed study in the appropriate population.
12. Does the closure of the wound mean complete tissue regeneration?
No. Closure is one of the outcomes, whereas tissue durability, symptoms, recurrence, and function may require separate measurements. A study demonstrating one of these outcomes should not be presented as confirmation of all others. The endpoint must remain linked to the claim. The wound may appear closed, while tissue architecture and its mechanical properties continue to change. Recurrence, pain, infections, and recovery of function may be evaluated separately. Detailed reporting indicates a specific endpoint, rather than treating each beneficial measure related to healing as a complete reconstruction.
13. Do the results of animal studies allow predicting the magnitude of the benefits in humans?
Not in a reliable way, if they are the only basis. Animal models allow us to study mechanisms and identify promising effects, but differences in disease, exposure, and physiology limit direct numerical extrapolation. The benefit in humans must be measured in an appropriate clinical study, not calculated based on the effect in animals. Animal models can reproduce selected aspects of injury, while at the same time differing from human disease and medical care. The magnitude of the effect in an animal experiment therefore does not constitute a reliable estimate of the effect in patients. Translational studies require clear comparisons of exposure and confirmation in humans.
14. Does the purity certificate confirm equivalence with a clinical product?
No. Purity is only one element of the characteristics. Identity, content, formulation, production control, and quality requirements specific to the route of administration also play a role. A certificate cannot transfer evidence from a clinical study to an unrelated product simply because it bears the same peptide name. A certificate can provide chromatographic purity without demonstrating peptide content, endotoxins, or stability. Products used in clinical studies have formulation and production specifications that may not be included in the overall certificate. Analytical similarity does not replace evidence of product equivalence.
15. Does the regulatory discussion mean the approval of the substance?
No. Advisory materials, assessments regarding the preparation of prescription drugs, and clinical trial registries serve different functions than marketing authorization. The FDA analysis regarding the fragment should be interpreted in accordance with its actual scope, without treating the meeting or document itself as an authorization for routine clinical use. [2] The regulatory agency’s advisory assessment may identify evidence gaps or safety issues without granting a license. Similarly, the registration of a clinical trial documents the study and its status, not a positive decision on efficacy. These sources should be described according to their actual function.
16. Can a small study rule out rare side effects?
No. A small trial has limited ability to detect rare events, and short observation does not allow to characterize all delayed effects. Tolerability results are useful during the period of the studied exposure, but broader safety conclusions require evidence from larger and appropriately monitored populations. If an adverse event occurs rarely, a small-number study may not detect any case despite the risk. Short studies also do not allow to characterize the consequences emerging over a long period. The absence of reported events constitutes evidence of limited sample size, long observation duration, and the method of data collection for safety.
17. Which studies would best explain the remaining uncertainties?
Appropriately sized, controlled studies targeting specific indications with previously defined primary endpoints would be most informative. They should feature precise formulation, report negative and positive results, and observe significant functional and safety outcomes. This would strengthen clinical conclusions more effectively than additional general claims about a „regenerative peptide.” The studies should distinguish full-length thymosin beta-4 from the defined fragment and specify each preparation. Supportive studies should prospectively identify endpoints and statistical methods, include appropriate control groups, and publish complete results. These steps would help to bridge the biggest gaps in current claims.
Interpretation of the evidence regarding TB-4 – identity, endpoints, and the possibility of generalization
Responsible interpretation begins with molecular identity. The full length of thymosin beta-4, the seven-residue fragment, and the finished ophthalmic product are not interchangeable research objects. Before considering any reported result, it is necessary to identify the exact substance, its preparation, and determine whether the study measured endogenous biology or tested material delivered from outside. This prevents the transfer of results between chemically distinct materials.
The next step is to identify the endpoint and the level of evidence. Actin binding is a molecular observation. Cell migration is a laboratory functional observation. Wound closure and eye surface staining are clinical measures specific to specific diseases. The overall clinical benefit requires a properly designed study in the appropriate population. A positive result at an earlier stage may justify further studies, but does not independently confirm subsequent stages.
In randomized studies, the primary endpoint and comparator require special attention. Differences between groups cannot be adequately described by simply stating that one group improved compared to the baseline value. Both groups may change due to standard care, natural recovery, or measurement variability. Similarly, an exploratory subgroup can provide information without confirming the overall treatment effect. Reporting of a previously defined analysis prevents selective emphasis on results.
The ability to generalize ultimately depends on the formulation, route of administration, exposure time, initial disease state, and length of observation. It cannot be assumed that the results regarding severe dry eye syndrome apply to tendon injuries, and the study of venous ulcers does not answer questions regarding athletic performance. The appropriate conclusion should not be broader than the question actually being tested in the study.
Research priorities and other questions
One of the main priorities is the independent replication of clinically relevant results using clearly defined full-length preparations. Published protocols, previously defined primary endpoints, and complete reporting of null and positive results would increase the reliability of comparisons. In the case of ophthalmological indications, repeated studies should clarify which signs and symptoms respond, how large the difference between groups is, and whether the changes persist after the evaluation period has ended.
In the wound studies, future trials would benefit from transparent descriptions of standard care, the characteristics of wounds, definitions of wound closure, recurrences, and long-term tissue outcomes. In cardiology studies, prospectively defined questions regarding the time of initiation of treatment and clinically relevant endpoints would help determine whether the reported signal in the subgroup is repeatable. Laboratory studies can continue to analyze actin regulation and signaling, but they should remain separate from clinical validation.
Fragment-specific studies constitute another important gap. The heptaresin N-acetylated fragment should be characterized and studied directly, rather than treating it as a shorter name for the intact 43-residue molecule. Comparative structural analysis, stability assessment, and appropriately controlled biological experiments would help determine which observations, if any, are common.
For each proposed clinical application, long-term safety data specific to the route of administration are also needed. The quality and stability of the administered material should be documented, including limitations of analytical studies of identity and purity. Better evidence would allow for clarification not only of whether an effect exists, but also of its magnitude, repeatability, and relevance to the target population.
Educational, medical and regulatory reservations
This article serves solely for the scientific and educational discussion of the identity of thymosin beta-4, its molecular biology, and published research. It does not constitute medical advice or instructions for the acquisition, preparation, administration, injection, or administration of TB-4 or TB-500 in any other form.
The results of experiments, clinical trial registrations, and advisory documents do not independently confirm the marketing authorization, safety, or efficacy of a specific commercial product. Regulatory status depends on the product and jurisdiction and should be verified in current official registries. Clinical decisions require evaluation by appropriately qualified specialists. The presented evidence should not be used to replace established medical care with unverified peptide products.
Conclusions
Thymosin beta-4 has a defined biological identity and is the subject of numerous scientific studies. Its well-known cellular functions must be distinguished from ambiguous clinical evidence regarding specific preparations. The full length of TB-4, fragments such as TB-500, and unrelated commercial products cannot be considered as alternative sources of evidence of efficacy or safety.
References
- Safer, D., Elzinga, M., & Nachmias, V. T. (1991). Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. The Journal of Biological Chemistry, 266(7), 4029–4032. https://pubmed.ncbi.nlm.nih.gov/1999398/
- U.S. Food and Drug Administration. (2026, July 23–24). Pharmacy Compounding Advisory Committee meeting: Thymosin beta-4 fragment (TB-500) [Meeting presentation]. https://www.fda.gov/media/193773/download
- UniProt Consortium. (n.d.). Thymosin beta-4: P62328 (TYB4_HUMAN) [Protein record]. Retrieved October 26, 2026, from https://www.uniprot.org/uniprotkb/P62328/entry
- Guarnera, G., DeRosa, A., Camerini, R., & 8 European sites. (2010). The effect of thymosin treatment of venous ulcers. Annals of the New York Academy of Sciences, 1194, 207–212. https://doi.org/10.1111/j.1749-6632.2010.05490.x
- Sosne, G., Dunn, S. P., & Kim, C. (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea, 34(5), 491–496. https://doi.org/10.1097/ICO.0000000000000379
- Sosne, G., & Ousler, G. W. (2015). Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clinical Ophthalmology, 9, 877-884. https://doi.org/10.2147/OPTH.S80954
- ReGenTree, LLC. (n.d.). Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3 (NCT03937882) [Clinical trial registry record]. ClinicalTrials.gov. Retrieved October 26, 2026, from https://clinicaltrials.gov/study/NCT03937882
- Sosne, G., Kleinman, H. K., Springs, C., Gross, R. H., Sung, J., & Kang, S. (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. International Journal of Molecular Sciences, 24(1), Article 554. https://doi.org/10.3390/ijms24010554
- Zhang, Y., Dong, Q., Bian, X., Qiao, Z., Cui, C., Yang, N., Liu, J., Fu, R., Zhang, J., Jia, L., Wu, C., Guo, J., Lin, W., Wang, J., Fan, J., Li, Y., Liu, F., Yang, B., Jia, X., … Dou, K. (2025). Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovascular Research, 121(17), 2747–2758. https://doi.org/10.1093/cvr/cvaf223